Brought to you by 
Infinity, MedImmune, AZ restructure Hedgehog deal
03 Dec 2015
Executive Summary
MedImmune and cancer drug company Infinity Pharmaceuticals will jointly develop and commercialize small-molecule cancer therapeutics aimed at heat shock protein 90 (Hsp90) and the Hedgehog cell-signaling pathway.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Infinity, MedImmune, AZ restructure Hedgehog deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice